Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Illinois Tool Works Inc. (ITW) vs Invesco Ltd. (IVZ) Price & Performance

Illinois Tool Works Inc.Trade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

Illinois Tool Works Inc. vs Invesco Ltd. — how do they compare? Illinois Tool Works Inc. trades at $293.41 (market cap $83.49B), while Invesco Ltd. trades at $31.52 (market cap $13.85B). The key difference: Illinois Tool Works Inc. is far larger — about 6× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.74%). Which is the better fit depends on your goals.

ITWIVZ
Market Cap
$83.49B$13.85B
Sector
IndustrialsFinancials
52-Week High
$299.60$32.01
52-Week Low
$241.07$20.67
Enterprise Value
$92.34B$24.01B
Dividend Yield
2.35%2.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illinois Tool Works Inc.

ITW trades at $293.66, down 0.29% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 19.39% net income margin and 104.65% ROE, though valuations appear elevated at P/E 26.55 and P/B 28.85. Recent Q2 2026 earnings beat expectations at $2.84 EPS, and management raised full-year guidance amid manufacturing sector recovery. The company announced a 7% dividend increase and $6 billion share repurchase program in August 2026.

Outlook remains positive with analyst consensus target of $314.25 offering 7% upside potential. Key catalysts include continued manufacturing recovery and margin expansion from the 80/20 program. Risks include premium valuation concerns and potential organic sales declines masked by currency gains. Institutional sentiment is mixed with 21% buy ratings versus 32% sell recommendations.

Invesco Ltd.

Invesco (IVZ) trades at $31.52, down 0.69% today, near its consensus price target of $32.50. The stock shows a bullish technical signal with moving averages supporting an uptrend, while recent earnings have been mixed with Q2 2026 beating expectations. Revenue grew to $6.38 billion in 2025, though net income was negative. Analyst sentiment is balanced with 12 buy and 16 hold ratings, and the company maintains a stable dividend.

The outlook for IVZ hinges on sustained asset under management growth and expense control to return to profitability. Key risks include market volatility affecting AUM and competitive pressures. Upside potential exists if operational improvements continue, but investors face uncertainty from inconsistent earnings performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Illinois Tool Works Inc.

Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.

Read more on ITW

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ